What Is Agouti-Related Peptide? Definition and What Research Reports

Definition

Agouti-related peptide (commonly abbreviated AgRP, and sometimes written “agouti-related protein”) is an endogenous neuropeptide encoded by the AGRP gene and produced chiefly by a small, well-defined group of neurons in the arcuate nucleus of the hypothalamus. It is classified pharmacologically as an antagonist and inverse agonist at central melanocortin receptors — principally MC3R and MC4R — meaning it acts in functional opposition to α-melanocyte-stimulating hormone (α-MSH), the melanocortin peptide cleaved from pro-opiomelanocortin (POMC). Because the neurons that make AgRP typically co-express neuropeptide Y (NPY) and the inhibitory transmitter GABA, the scientific literature often refers to them collectively as “NPY/AgRP neurons” or “AgRP hunger neurons.” This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment.

What Class of Molecule Is It?

AgRP belongs to the family of hypothalamic neuropeptides — short chains of amino acids released by neurons that act on receptors in the brain rather than being secreted as classical endocrine hormones from a gland. Its name comes from its structural similarity to agouti signalling protein, the coat-colour protein first described in mice, which antagonises melanocortin receptors in skin. AgRP is the central-nervous-system counterpart: a cysteine-rich peptide whose active C-terminal domain docks at melanocortin receptors.

Where It Comes From

The dominant source is the arcuate nucleus of the hypothalamus, a region positioned near the median eminence where circulating metabolic signals can reach neurons. AgRP is also detectable in peripheral tissues, including the adrenal gland, and a form of the peptide circulates in blood, which is why some clinical research measures plasma AgRP as a potential marker rather than studying it as an administered substance.

How the Term Is Used in Peptide Research

In most published work, “AgRP” is used in one of three ways:

• As a cell-type label. “AgRP neurons” identifies the arcuate population defined by Agrp expression, which researchers can activate, inhibit or record using genetic and optical tools.
• As a molecular species. The peptide itself, or its fragments, is studied for receptor binding and for antagonism of melanocortin signalling.
• As a measurable analyte. Concentrations of AgRP in plasma or tissue are quantified and compared between groups in observational clinical studies.

This matters for anyone reading the literature: a great deal of AgRP research is neuroscience performed in laboratory animals using circuit-manipulation techniques, not pharmacology in which a peptide is given to a subject. Findings about “AgRP neurons” describe what happened when cells were switched on or off, which is a different kind of evidence from a dosing study.

What the Published Literature Reports

Regulation of AgRP neurons over time

A 2025 Cell Metabolism study examined acute and circadian feedforward regulation of agouti-related peptide hunger neurons, reporting that the activity of these neurons is shaped both by immediate cues and by time-of-day signalling rather than by hunger state alone (PMID 39719709). The study is frequently cited as evidence that AgRP neuron output is anticipatory as well as reactive.

Diet, nutrients and cellular environment

Researchers publishing in Molecular Metabolism in 2025 described fructose-induced synaptic and neuronal adaptations at neuropeptide Y/agouti-related peptide neurons, indicating that a specific dietary sugar was associated with measurable changes at the level of synapses onto these cells (PMID 40653085). Separately, a 2024 Cell Reports paper reported that iron overload in hypothalamic AgRP neurons contributed to obesity and related metabolic disorders in the models used (PMID 38460132). Both reports situate AgRP neurons as cells whose internal state and synaptic inputs can be altered by nutritional and micronutrient factors.

Development and reproductive timing

A 2022 study in the Journal of Neuroendocrinology reported that agouti-related peptide neuronal silencing overcame delayed puberty in neonatally underfed male mice, linking the activity of this hypothalamic population to the timing of reproductive maturation under early-life nutritional restriction (PMID 36306199). The finding is one line of evidence that AgRP circuits interface with systems beyond feeding.

AgRP as a measured biomarker in humans

A large single-centre cross-sectional analysis published in the European Journal of Endocrinology in 2025 described agouti-related peptide as a promising prognostic biomarker in adrenocortical carcinoma (PMID 41172328). In that setting AgRP was measured, not administered — an important distinction when interpreting human AgRP literature.

AgRP and Related Terms

Safety and Adverse Events: What Studies Report

The verified literature summarised here does not describe administration of agouti-related peptide to human participants, and therefore reports no dosing schedule, tolerability profile or adverse-event data for such use. The rodent work involved genetic and circuit-level manipulation of AgRP neurons — for example the silencing approach described in the puberty study (PMID 36306199) — rather than injection of the peptide itself. The human data point in this set is observational measurement of AgRP in patients with adrenocortical carcinoma (PMID 41172328). Any safety statement about AgRP as an administered compound would go beyond what these papers report.

How to Read AgRP Findings

1. Check whether the peptide or the neuron was studied. Manipulating AgRP neurons also manipulates NPY and GABA release from the same cells, so effects are not necessarily attributable to the peptide alone.
2. Check the species and model. Four of the five studies cited here are laboratory work; only the biomarker analysis involved human samples (PMID 41172328).
3. Check the direction of the claim. A biomarker association — AgRP levels tracking with prognosis — is not a statement that the peptide caused the outcome.
4. Check the timing context. Because AgRP neuron activity varies with circadian and anticipatory cues, as the 2025 Cell Metabolism study reported, measurements taken at different times are not automatically comparable (PMID 39719709).

Regulatory and Research Status

Agouti-related peptide is an endogenous human peptide and a research subject; it is not an approved drug product. Peptide materials of this type sold to laboratories are typically labelled for research use only. The melanocortin system that AgRP acts on is, by contrast, the target of several approved and investigational agents developed independently of AgRP itself.

Key Points

• AgRP is an endogenous neuropeptide, classified as a melanocortin-receptor antagonist, produced mainly by arcuate hypothalamic neurons.
• The term commonly denotes a neuron population (“AgRP neurons”, often NPY/AgRP) as much as the peptide.
• Published work has reported circadian and feedforward regulation of these neurons (PMID 39719709), dietary and iron-linked changes in them (PMID 40653085, PMID 38460132), an effect of silencing them on pubertal timing in underfed male mice (PMID 36306199), and interest in circulating AgRP as a prognostic marker (PMID 41172328).

References

• Iron overload in hypothalamic AgRP neurons contributes to obesity and related metabolic disorders (Cell Reports, 2024)
• Fructose-induced synaptic and neuronal adaptations at neuropeptide Y/agouti-related peptide neurons (Molecular Metabolism, 2025)
• Acute and circadian feedforward regulation of agouti-related peptide hunger neurons (Cell Metabolism, 2025)
• Agouti-related peptide neuronal silencing overcomes delayed puberty in neonatally underfed male mice (Journal of Neuroendocrinology, 2022)
• Agouti-related peptide: a promising prognostic biomarker in adrenocortical carcinoma. Results from a large single-centre cross-sectional analysis (European Journal of Endocrinology, 2025)